Kushlinskii N E, Gershtein E S, Ivannikov A A, Davydov M M, Chang V L, Ognerubov N A, Stilidi I S
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia.
G. R. Derzhavin Tambov State University, Tambov, Russia.
Bull Exp Biol Med. 2019 Jan;166(3):373-376. doi: 10.1007/s10517-019-04353-y. Epub 2019 Jan 9.
Plasma levels of MMP-2, MMP-7, and MMP-9 and their tissue inhibitor TIMP-2 were measured in 89 patients with gastric cancer and the relationship between these parameters and the main clinical morphological characteristics of the disease was analyzed. Plasma levels of the proteins were measured using standard direct ELISA kits. The level of MMP-7 in patients with gastric cancer was significantly higher than in the control group (medians 2.7 and 1.2 ng/ml, respectively; p<0.01), but only in 51% patients this parameter surpassed the upper threshold normal value (2.35 ng/ml; 95% percentile of control). The level of MMP-9 in gastric cancer patients was lower than in control group by 1.6 times (medians 167 and 267 ng/ml, respectively; p<0.01). Plasma levels of MMP-2 and TIMP-2 in patients with gastric cancer and healthy subjects were similar. No appreciable associations of plasma matrixins and TIMP-2 with the main clinical morphological characteristics of the disease were detected. The patients were followed up for 8 to 85 months (median 70.8 months). Low level of MMP-2 and high level of MMP-7 in the plasma proved to be unfavorable prognostic factors for overall survival. At MMP-2<268 ng/ml, the 5-year overall survival was 32% vs. 60% for patients with the marker level higher than this threshold value (p=0.016). The differences in overall survival in relation to their MMP-7 levels for 5-year observation did not surpass 16% (39% at marker level >2.7 ng/ml and 55% at lower level; p=0.048). Plasma levels of MMP-2 and TIMP-2 were not significantly associated with overall survival. Multivariate analysis showed that only T index (p=0.034) and plasma MMP-7 level (p=0.007) were essential for overall survival. The increase in plasma or serum MMP-7 levels is a universal phenomenon in tumors of different histogenesis, which precluded the use of this parameter as a specific diagnostic marker of gastric cancer. At the same time, it could be useful for monitoring the treatment efficiency and detection of relapses. In addition, high plasma level of MMP-7 remained an independent factor of unfavorable prognosis for overall survival of patients with gastric cancer.
对89例胃癌患者测定了血浆基质金属蛋白酶-2(MMP-2)、基质金属蛋白酶-7(MMP-7)、基质金属蛋白酶-9(MMP-9)水平及其组织抑制剂金属蛋白酶组织抑制因子-2(TIMP-2),并分析了这些参数与该疾病主要临床形态学特征之间的关系。使用标准直接酶联免疫吸附测定试剂盒测定蛋白质的血浆水平。胃癌患者的MMP-7水平显著高于对照组(中位数分别为2.7和1.2 ng/ml;p<0.01),但仅51%的患者该参数超过正常上限值(2.35 ng/ml;对照组的第95百分位数)。胃癌患者的MMP-9水平比对照组低1.6倍(中位数分别为167和267 ng/ml;p<0.01)。胃癌患者和健康受试者的血浆MMP-2和TIMP-2水平相似。未检测到血浆基质金属蛋白酶和TIMP-2与该疾病主要临床形态学特征有明显关联。对患者进行了8至85个月的随访(中位数为70.8个月)。血浆中MMP-2水平低和MMP-7水平高被证明是总生存的不良预后因素。当MMP-2<268 ng/ml时,5年总生存率为32%,而标志物水平高于此阈值的患者为60%(p=0.016)。5年观察期内,根据MMP-7水平的总生存率差异未超过16%(标志物水平>2.7 ng/ml时为39%,较低水平时为55%;p=0.048)。血浆MMP-2和TIMP-2水平与总生存率无显著关联。多因素分析表明,仅T指数(p=0.034)和血浆MMP-7水平(p=0.007)对总生存至关重要。血浆或血清MMP-7水平升高是不同组织发生肿瘤中的普遍现象,这使得该参数不能用作胃癌的特异性诊断标志物。同时,它可能有助于监测治疗效果和检测复发。此外,血浆MMP-7水平高仍然是胃癌患者总生存不良预后的独立因素。